Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Presbyopia
Interventions: Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3, Placebo Ophthalmic Topical Cream; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 40 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 10
States / cities: Chandler, Arizona • Sun City, Arizona • Glendale, California + 7 more

Conditions: Healthy
Interventions: Paroxetine Hydrochloride Controlled-Release Tablets 25 mg, Paxil CR™ Tablets 25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Alzheimer's Disease
Interventions: T3D-959, Placebo Comparator; Drug · Other
Lead sponsor: T3D Therapeutics, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Supracondylar Humerus Fracture
Interventions: Ibuprofen, Oxycodone, Acetaminophen; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 4 Years to 12 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Asthma
Interventions: Dose 4 QD, Dose 3 QD, placebo, Dose 2 QD, Dose 1 BD; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Cypress, California • Huntington Beach, California • Bethesda, Maryland + 6 more

Conditions: Healthy
Interventions: Daratumumab, Placebo, rHuPH20; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Cardiovascular Diseases
Interventions: Pecans, Usual Care; Drug · Other
Lead sponsor: Penn State University; Other
Eligibility: 25 Years to 70 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Diabetes Mellitus
Interventions: FK614; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 36
States / cities: Ozark, Alabama • Tucson, Arizona • Cypress, California + 29 more

Conditions: Suicide, Depressive Disorder, Major, Anxiety Disorders, Suicidal Ideation, Suicidal Impulses
Interventions: Standard of Care, Crisis Intervention, Wraparound Services; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 10 Years to 18 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Rheumatoid Arthritis
Interventions: Pedometer, Educational materials, Step count goals; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted, Placebo; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 51 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • New York, New York

Conditions: Scar, Skin Scarring, Skin Cancer, Wound Heal, Wound of Skin, Surgical Wound, Patient Satisfaction, Patient Preference, Surgical Incision
Interventions: Hydrocolloid dressing, Petrolatum jelly dressing; Device · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Carmel, Indiana

Conditions: Idiopathic Normal Pressure Hydrocephalus (INPH)
Interventions: programmable CSF shunt valve; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 14
States / cities: Davis, California • Los Angeles, California • Santa Monica, California + 10 more

Conditions: ACTINIC KERATOSIS
Interventions: Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 23
States / cities: Oceanside, California • Denver, Colorado • Aventura, Florida + 20 more

Conditions: Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Interventions: VERVE-102, Placebo; Drug
Lead sponsor: Verve Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: DeSoto, Texas

Conditions: Neuropathic Pain
Interventions: Auricular acupuncture; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Inflammatory Bowel Disease
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: University of South Alabama; Other
Eligibility: 19 Years to 90 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Mobile, Alabama

Conditions: Virtual Reality Amnesia
Interventions: Immersive Virtual Reality, Plausible control condition; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Nutrition, Diet Interventions
Interventions: Control label, Added sugar warning; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 543 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Analgesic Efficacy
Interventions: Suzetrigine, acetaminophen; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Huntington's Disease
Interventions: SAGE-718, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 34
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 28 more

Conditions: Symptomatic Orthostatic Hypotension
Interventions: Midodrine HCl, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 18
States / cities: Glendale, California • North Hollywood, California • Boca Raton, Florida + 15 more

Conditions: Migraine
Interventions: Saline, lidocaine/bupivacaine; Drug · Combination Product
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Rhinitis, Allergic, Perennial
Interventions: FPNS, FFNS, placebo FFNS, placebo FPNS; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 20 more

Search by objective public record fields.

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia

Food Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg

A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

Supracondylar Post-Operative Pain Study

Efficacy and Safety Study in Subjects With Asthma

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants

Cardiometabolic Effects of Pecans as a Snack

Trial of FK614 in Type 2 Diabetics Inadequately Controlled on a Sulfonylurea

Promote Access to Stop Suicide: Comparison of Follow up Services for Youth at Risk for Suicide

Trial of a Physical Activity Intervention for RA Fatigue

A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults

Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment

Efficacy in iNPH Shunting (PENS) Trial

An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis

A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

Ear Acupuncture for Neuropathic Pain

Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy

The Effect of Immersive VR Distraction on Memory: Study 2

Impacts of Sugar Warnings on Weight Bias

Suzetrigine Frame Trial Comparing Suzetrigine and Acetaminophen

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension

A Research Study of Greater Occipital Nerve Block as a Treatment for Acute Migraine Attacks

Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS